

STATIN THERAPY INITIATED:

- ❖ Assess adherence and response to statin therapy at 4-12 weeks based on lifestyle changes and statin therapy

(LDL reduction achieved)



(LDL reduction not achieved)

- ❖ **Maximize Statin** to tolerated intensity
- ❖ **Change statin** based on patient tolerance or adverse effects
- ❖ Assess adherence and response to statin therapy at 4-12 weeks based on lifestyle changes and statin therapy

(LDL reduction achieved)



(LDL reduction not achieved)

- ❖ **Add Ezetimibe 10mg daily** (additional 20% LDL reduction)
- ❖ Assess adherence and response to statin therapy at 4-12 weeks based on lifestyle changes and statin therapy

(LDL reduction achieved)



(LDL reduction not achieved)

- ❖ **Consider referral** (cardiology, endocrinology)
 - ❖ Consider the following options:
 - Repatha 140mg sq every two weeks or 420mg monthly
 - Praluent 75mg sq every two weeks, or 300mg every 4 weeks
 - Nexletol 180mg daily
 - Leqvio 284mg sq initial, 3 months, then every 6 months
- [*Note Evolocumab (Repatha) FOURIER study showed CV mortality reduction]

✓ Recheck in 3-12 months, monitor statin adherence and lifestyle changes

NOTE: When assessing Triglyceride lowering needs (TG \geq 150 mg/dL + ASCVD or DM w/ \geq 2 risk factors), may add Icosapent Ethyl 2gm BID [*Note: Reduce-IT study demonstrated CV mortality reduction]